Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: J Cancer Surviv. 2020 Jan 13;14(2):226–234. doi: 10.1007/s11764-019-00815-4

Table 3.

Study 3 sample demographics at screen

PPI Users (n=21) PPI Non-users (n=121)

Measure N (%) M (SD) N (%) M (SD)
Age 55.7(9.1) 55.6(7.7)
Comorbidities 0.3(0.6) 0.2(0.5)
Months since cancer tx 53.1(19.9) 43.0(27.7)
Race (% White) 20(95%) 106(88%)
Education High School 6(29%) 16(13%)
Some College 2(10%) 25(21%)
College Grad 6(29%) 37(31%)
Grad Training 7(33%) 43(34%)
Chemo tx (% Yes) 16(80%) 88(73%)
Hormone tx (% Yes) 14(65%) 95(79%)
Radiation tx (% Yes) 9(43%) 68(56%)
CES-D score 9.1(8.0) 7.1(7.3)
Cancer Stage Stage I 6(29%) 50(41%)
Stage II 11(52%) 63(52%)
Stage III 1(5%) 8(7%)
*

p<0.05